Recent advances in the understanding of the role of the endocannabinoid system in liver diseases

Digestive and Liver Disease

Volumn 43, Issue 3, 2011, Pages 188-193

  Huang, Li ^a,b,c   Quinn, Matthew A ^a,b   Frampton, Gabriel A ^a   Golden, Lessie Eric ^a   DeMorrow, Sharon ^a,b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cannabinoid receptors; Novel therapeutic strategies

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID RECEPTOR; ENDOCANNABINOID; RIMONABANT;

CELL PROLIFERATION; CHOLESTATIC HEPATITIS; CHRONIC LIVER DISEASE; HEART DISEASE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER ISCHEMIA; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; END STAGE LIVER DISEASE; ENDOCANNABINOIDS; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; LIVER FAILURE, ACUTE; LIVER NEOPLASMS; RECEPTORS, CANNABINOID; REPERFUSION INJURY;

EID: 79551483215     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.08.010     Document Type: Review

References (68)

1. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998, 394:277-281.
2. Manzanares J., Corchero J., Romero J., Fernandez-Ruiz J.J., Ramos J.A., Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 1999, 20:287-294.
3. Voth E.A., Schwartz R.H. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med 1997, 126:791-798.
4. Piomelli D., Giuffrida A., Calignano A., Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000, 21:218-224.
5. Baker D., Pryce G., Croxford J.L., et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000, 404:84-87.
6. De Petrocellis L., Melck D., Palmisano A., et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 1998, 95:8375-8380.
7. Ruiz L., Miguel A., Diaz-Laviada I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate pc-3 cells via a receptor-independent mechanism. FEBS Lett 1999, 458:400-404.
8. Sanchez C., de Ceballos M.L., del Pulgar T.G., et al. Inhibition of glioma growth in vivo by selective activation of the cb(2) cannabinoid receptor. Cancer Res 2001, 61:5784-5789.
9. Sanchez C., Galve-Roperh I., Canova C., Brachet P., Guzman M. Delta9-tetrahydrocannabinol induces apoptosis in c6 glioma cells. FEBS Lett 1998, 436:6-10.
10. Galve-Roperh I., Sanchez C., Cortes M.L., del Pulgar T.G., Izquierdo M., Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000, 6:313-319.
11. Bisogno T., Ligresti A., Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav 2005, 81:224-238.
12. Ryberg E., Larsson N., Sjogren S., et al. The orphan receptor gpr55 is a novel cannabinoid receptor. Br J Pharmacol 2007, 152:1092-1101.
13. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988, 34:605-613.
14. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cdna. Nature 1990, 346:561-564.
15. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
16. Di Marzo V., Deutsch D.G. Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol Dis 1998, 5:386-404.
17. Glaser S.T., Kaczocha M., Deutsch D.G. Anandamide transport: a critical review. Life Sci 2005, 77:1584-1604.
18. Caraceni P., Viola A., Piscitelli F., et al. Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int 2009.
19. Biswas K.K., Sarker K.P., Abeyama K., et al. Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosis. Hepatology 2003, 38:1167-1177.
20. Osei-Hyiaman D., DePetrillo M., Pacher P., et al. Endocannabinoid activation at hepatic cb1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005, 115:1298-1305.
21. Siegmund S.V., Qian T., de Minicis S., et al. The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J 2007, 21:2798-2806.
22. Siegmund S.V., Seki E., Osawa Y., Uchinami H., Cravatt B.F., Schwabe R.F. Fatty acid amide hydrolase determines anandamide-induced cell death in the liver. J Biol Chem 2006, 281:10431-10438.
23. Lotersztajn S., Julien B., Teixeira-Clerc F., Grenard P., Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2005, 45:605-628.
24. Julien B., Grenard P., Teixeira-Clerc F., et al. Antifibrogenic role of the cannabinoid receptor cb2 in the liver. Gastroenterology 2005, 128:742-755.
25. Teixeira-Clerc F., Julien B., Grenard P., et al. Cb1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006, 12:671-676.
26. Teoh N.C., Farrell G.C. Hepatic ischemia reperfusion injury: pathogenic mechanisms and basis for hepatoprotection. J Gastroenterol Hepatol 2003, 18:891-902.
27. Serracino-Inglott F., Habib N.A., Mathie R.T. Hepatic ischemia-reperfusion injury. Am J Surg 2001, 181:160-166.
28. Rajesh M., Pan H., Mukhopadhyay P., et al. Cannabinoid-2 receptor agonist hu-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol 2007, 82:1382-1389.
29. Marzioni M., Saccomanno S., Candelaresi C., et al. Clinical implications of novel aspects of biliary pathophysiology. Dig Liver Dis 2010, 42:238-244.
30. DeMorrow S., Francis H., Gaudio E., et al. Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and ap-1 activation. Am J Physiol Gastrointest Liver Physiol 2008, 294:G506-519.
31. Magen I., Avraham Y., Berry E., Mechoulam R. Endocannabinoids in liver disease and hepatic encephalopathy. Curr Pharm Des 2008, 14:2362-2369.
32. Butterworth R.F., Giguere J.F., Michaud J., Lavoie J., Layrargues G.P. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987, 6:1-12.
33. Mousseau D.D., Baker G.B., Butterworth R.F. Increased density of catalytic sites and expression of brain monoamine oxidase a in humans with hepatic encephalopathy. J Neurochem 1997, 68:1200-1208.
34. Rao V.L., Giguere J.F., Layrargues G.P., Butterworth R.F. Increased activities of maoa and maob in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Brain Res 1993, 621:349-352.
35. Rao V.L., Butterworth R.F. Alterations of [3h]8-oh-dpat and [3h]ketanserin binding sites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Neurosci Lett 1994, 182:69-72.
36. Yurdaydin C., Karavelioglu D., Onaran O., Celik T., Yasa M.H., Uzunalimoglu O. Opioid receptor ligands in human hepatic encephalopathy. J Hepatol 1998, 29:796-801.
37. Jalan R., Turjanski N., Taylor-Robinson S.D., et al. Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis. Gut 2000, 46:546-552.
38. Ahboucha S., Pomier-Layrargues G., Butterworth R.F. Increased brain concentrations of endogenous (non-benzodiazepine) gaba-a receptor ligands in human hepatic encephalopathy. Metab Brain Dis 2004, 19:241-251.
39. Avraham Y., Israeli E., Gabbay E., et al. Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. Neurobiol Dis 2006, 21:237-245.
40. Dagon Y., Avraham Y., Ilan Y., Mechoulam R., Berry E.M. Cannabinoids ameliorate cerebral dysfunction following liver failure via amp-activated protein kinase. FASEB J 2007, 21:2431-2441.
41. Caraceni P., Domenicali M., Giannone F., Bernardi M. The role of the endocannabinoid system in liver diseases. Best Pract Res Clin Endocrinol Metab 2009, 23:65-77.
42. Song D., Liu H., Sharkey K.A., Lee S.S. Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression. Hepatology 2002, 35:159-166.
43. Moezi L., Gaskari S.A., Lee S.S. Endocannabinoids and liver disease. V. Endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis. Am J Physiol Gastrointest Liver Physiol 2008, 295:G649-653.
44. Gaskari S.A., Liu H., Moezi L., Li Y., Baik S.K., Lee S.S. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol 2005, 146:315-323.
45. Moezi L., Gaskari S.A., Liu H., Baik S.K., Dehpour A.R., Lee S.S. Anandamide mediates hyperdynamic circulation in cirrhotic rats via cb(1) and vr(1) receptors. Br J Pharmacol 2006, 149:898-908.
46. Bosch F.X., Ribes J., Diaz M., Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
47. Thomas M.B., Zhu A.X. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005, 23:2892-2899.
48. Xu X., Liu Y., Huang S., et al. Overexpression of cannabinoid receptors cb1 and cb2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 2006, 171:31-38.
49. Giuliano M., Pellerito O., Portanova P., et al. Apoptosis induced in hepg2 cells by the synthetic cannabinoid win: involvement of the transcription factor ppargamma. Biochimie 2009, 91:457-465.
50. Pellerito O., Calvaruso G., Portanova P., et al. The synthetic cannabinoid win 55,212-2 sensitizes hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (trail)-induced apoptosis by activating p8/ccaat/enhancer binding protein homologous protein (chop)/death receptor 5 (dr5) axis. Mol Pharmacol 2010, 77:854-863.
51. Alpini G., Prall R., LaRusso N.F. The pathobiology of biliary epithelia. LiverBiol Pathobiol 2001, 4E:421-435.
52. Sirica A.E. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005, 41:5-15.
53. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002, 2:10.
54. Tominaga S., Kuroishi T. Biliary tract cancer. Cancer Surv 1994, 19-20:125-137.
55. DeMorrow S., Glaser S., Francis H., et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of fas and fas ligand to lipid rafts. J Biol Chem 2007, 282:13098-13113.
56. DeMorrow S., Francis H., Gaudio E., et al. The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the non-canonical wnt signaling pathway. Am J Physiol Gastrointest Liver Physiol 2008, 295:G1150-1158.
57. Frampton G., Coufal M., Li H., Ramirez J., DeMorrow S. Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of notch signaling. Experimental Cell Res 2010, 316:1465-1478.
58. Kopan R., Goate A. Aph-2/nicastrin: an essential component of gamma-secretase and regulator of notch signaling and presenilin localization. Neuron 2002, 33:321-324.
59. Lai E.C. Notch cleavage: nicastrin helps presenilin make the final cut. Curr Biol 2002, 12:R200-202.
60. Lee S.F., Shah S., Li H., Yu C., Han W., Yu G. Mammalian aph-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-beta precursor protein and notch. J Biol Chem 2002, 277:45013-45019.
61. Li T., Ma G., Cai H., Price D.L., Wong P.C. Nicastrin is required for assembly of presenilin/gamma-secretase complexes to mediate notch signaling and for processing and trafficking of beta-amyloid precursor protein in mammals. J Neurosci 2003, 23:3272-3277.
62. Gamerdinger M., Clement A.B., Behl C. Effects of sulindac sulfide on the membrane architecture and the activity of gamma-secretase. Neuropharmacology 2008, 54:998-1005.
63. Ristorcelli E., Beraud E., Mathieu S., Lombardo D., Verine A. Essential role of notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles. Int J Cancer 2009, 125:1016-1026.
64. Collu G.M., Brennan K. Cooperation between wnt and notch signalling in human breast cancer. Breast Cancer Res 2007, 9:105.
65. Katoh M. Transcriptional mechanisms of wnt5a based on nf-kappab, hedgehog, tgfbeta, and notch signaling cascades. Int J Mol Med 2009, 23:763-769.
66. Nakamura T., Tsuchiya K., Watanabe M. Crosstalk between wnt and notch signaling in intestinal epithelial cell fate decision. J Gastroenterol 2007, 42:705-710.
67. Koyanagi M., Bushoven P., Iwasaki M., Urbich C., Zeiher A.M., Dimmeler S. Notch signaling contributes to the expression of cardiac markers in human circulating progenitor cells. Circ Res 2007, 101:1139-1145.
68. Izzo A.A., Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 2008, 57:1140-1155.